FDA Demands Tobacco Companies Prove They Sold Here First
Published Date: 9/29/2025
Notice
Summary
The FDA is asking for approval to collect info from tobacco companies about how they prove their products were sold in the U.S. This helps make sure only legal tobacco products are on the market. Tobacco businesses should get ready for new paperwork soon, but no big costs are expected right now.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Tobacco firms must ready new paperwork
The FDA is asking OMB to approve a new information collection under the Paperwork Reduction Act of 1995 that asks tobacco companies to show how their products were commercially marketed in the United States. Tobacco businesses should prepare for new paperwork soon, though the FDA says no big costs are expected right now.
Aims to keep only legal tobacco for sale
The FDA says the information collection is meant to help ensure that only tobacco products that were legally commercially marketed in the United States remain on the market. If effective, this action is intended to reduce the presence of illegally marketed tobacco products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-18803 — Presidential Declaration of a Major Disaster for Public Assistance Only for the State of Kansas
The President has declared a major disaster in Kansas because of severe storms, tornadoes, and flooding. This means local communities can get special help to fix public buildings and services. The aid starts right away to help Kansas bounce back faster and stronger.
Next: 2025-18809 — Determination of Regulatory Review Period for Purposes of Patent Extension; NIKTIMVO
The FDA has officially set the review period for NIKTIMVO, a human biological product, so its patent can be extended. This helps the company behind NIKTIMVO get extra time to protect their invention. If you’re involved in patents or drug development, this timing update matters for planning and legal steps.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in